3 Legacy Health Care Dividend Stocks That Never Go Out of Style

Johnson & Johnson (JNJ), Abbott Laboratories (ABT), and Medtronic (MDT) are highlighted for their long dividend growth streaks and steady demand in healthcare. JNJ, with a 64-year streak, aims for $100B revenue, yields 1.91%, and has a AAA credit rating. ABT, a Dividend Aristocrat, yields 2.28% and focuses on aging population growth. MDT offers the highest yield at 2.77% and the lowest forward multiple. All three cover payouts with adjusted earnings and free cash flow.

Original reporting
Published Nov 11, 2026, 3:17 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 3:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
3 Legacy Health Care Dividend Stocks That Never Go Out of Style — source image
Decision brief

The 30-second read

$JNJNeutralLow
01

Why it matters

While each company raised its dividend, the increases are modest and largely expected, offering limited new trading opportunities.

02

Market read

The piece serves as a dividend‑focus overview for income investors, with minimal immediate market impact.

03

What to watch

Potential litigation costs at JNJ and the upcoming Abbott nutrition spinoff could offset dividend benefits.

Relevance 4/10Novelty 3/10Timing: none

Background

The article profiles three legacy health‑care companies—Johnson & Johnson, Abbott Laboratories, and Medtronic—highlighting their long dividend‑increase streaks and recent payout changes.

Company-level read

Ticker impact

$JNJNeutralMedium confidence
Context

Johnson & Johnson announced its 64th consecutive dividend increase, raising the quarterly payout to $1.34 and provided FY free cash flow guidance of $21 billion.

Expected impact

potential modest upside as the higher dividend supports valuation

Evidence & confidence

The increase is incremental (3.1%) and aligns with the company's strong cash flow, offering limited upside pressure.

$ABTNeutralMedium confidence
Context

Abbott Laboratories reported a 54‑year dividend‑increase streak and disclosed a quarterly dividend of $0.63, with management indicating a future dividend increase.

Expected impact

limited upside as the dividend hike is expected and already priced in

Evidence & confidence

The news reiterates an existing trend without new material catalyst, so price impact is likely muted.

$MDTNeutralMedium confidence
Context

Medtronic announced its 49th consecutive dividend increase, raising the quarterly payout to $0.72 and provided FY non‑GAAP EPS guidance of $5.94‑$6.00.

Expected impact

slight upside potential as the dividend raise reinforces income appeal

Evidence & confidence

The increase is modest (one cent) and reflects ongoing cash‑flow strength, offering limited new price impetus.

Market effects

Reinforces the appeal of dividend‑focused health‑care stocks for income investors.

US‑listed health‑care dividend aristocrats may see modest buying pressure.

Limited; the story is US‑centric and does not affect broader markets.

Counterpoint

The incremental dividend hikes may not justify a price rally given modest growth and existing valuation.

Key entities

  • Johnson & Johnson

    US‑listed health‑care conglomerate with a 64‑year dividend streak.

  • Abbott Laboratories

    US‑listed medical‑device and diagnostics firm with a 54‑year dividend streak.

  • Medtronic

    US‑listed medical‑device maker with a 49‑year dividend streak.

Related articles

$JNJHighAI 9/10

ICONIC-ASCEND: Icotrokinra Tops Placebo, Matches Ustekinumab in Psoriasis

Johnson & Johnson's icotrokinra (Icotyde) outperformed placebo and was noninferior to ustekinumab in a phase 3 trial for moderate to severe plaque psoriasis. At week 16, 55.2% of patients on icotrokinra achieved PASI 90 vs. 3.6% on placebo. At week 28, icotrokinra was noninferior to ustekinumab, with numerically higher response rates but no statistical superiority. The drug is already approved in the US, Europe, Japan, and China.

$JNJLow

FDA Approval for LAZCLUZE issued to JANSSEN BIOTECH

The FDA approved a labeling update for J&J's LAZCLUZE (lazertinib) on 11/12/2026. The change, under supplement SUPPL-5, affects the package insert only, with no alteration to the drug's indication or efficacy. LAZCLUZE was originally approved on 08/19/2024. The drug is available in 80MG and 240MG tablet strengths. According to the filing, this is an administrative update for an already approved drug.

$GSKMedAI 8/10

Belantamab Mafodotin Moves Into Lenalidomide-Refractory Myeloma in Updated NCCN Guidelines

The NCCN updated its guidelines to include GSK's belantamab mafodotin (Blenrep) plus bortezomib and dexamethasone as a category 1 recommendation for lenalidomide-refractory multiple myeloma. The update also includes two other belantamab triplets under 'Useful in Certain Circumstances' for patients with 3 or more prior therapies. The changes follow the drug's FDA approval in October 2025 and reflect its efficacy in clinical trials.

$JNJHighAI 9/10

Oral IL-23 Antagonist Icotrokinra Improves PsA Symptoms

Johnson & Johnson's icotrokinra (Icotyde) showed improvement in psoriatic arthritis (PsA) symptoms at 16 weeks in a phase 3 trial, with 200-mg and 400-mg doses outperforming placebo. The drug, approved for psoriasis, is being studied for PsA, with no new safety signals identified. Experts highlight its potential as an oral treatment option. The trial compared icotrokinra to ustekinumab, with results showing efficacy and safety. Final 52-week data are pending.